Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Onglyza

Type 2 diabetes treatment from AstraZeneca and Bristol-Myers Squibb gets approval in the US

AstraZeneca and Bristol-Myers Squibb (BMS) have received US Food and Drug Administration (FDA) approval for Onglyza (saxagliptin) for the treatment of type 2 diabetes mellitus in adults.

Onglyza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. The once-daily dipeptidyl peptidase-4 (DPP-4) can be used in combination with commonly prescribed oral anti-diabetic medications, such as metformin, sulfonylureas and thiazolidinediones (TZDs), or as a monotherapy to significantly reduce glycosylated haemoglobin levels.

"Type 2 diabetes is a daily challenge for adults patients and physicians. With FDA approval of Onglyza, physicians and adult patients with type 2 diabetes have an important new treatment to help improve glycemic control," said David Brennan, AstraZeneca CEO.

DPP-4 affect the action of incretins; hormones that decrease elevated blood sugar levels by increasing the way the body uses sugar, mainly through increasing insulin production in the pancreas and by reducing the production of glucose in the liver.

The collaboration between AstraZeneca and BMS began in January 2007 with the aim of enabling the two companies to research, develop and commercialise select investigational drugs for type 2 diabetes. 

3rd August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics